DETECT III

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们的全球目标是评估接受阿霉素治疗的癌症患者的系列心血管磁共振（CMR）成像是否可用于识别永久性心脏损伤的左心室射血分数（LVEF）特征的晚期全球变化之前的早期心脏损伤，从而改善癌症幸存者生活质量的差异。为此，我们必须首先研究健康受试者的纵向变异性，以检测患者的显著差异。在初步研究中，我们已经获得了动态T1措施的纵向弛豫在动物模型的心脏毒性。在给予钆对比剂之后，在包围左心室的三个切片中对纵向反转恢复曲线进行采样。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is our global objective to assess whether serial cardiovascular magnetic resonance (CMR) imaging of cancer patients receiving doxorubicin can be used to identify early cardiac damage prior to late, global changes in left ventricular ejection fraction (LVEF) characteristic of permanent cardiac injury and thus improve disparities in the quality of life for cancer survivors. To do so, we must first investigate the longitudinal variability in healthy subjects to detect a significant difference in patients. In preliminary studies, we have obtained Dynamic T1 measures of longitudinal relaxation in an animal model of cardiotoxicity. After gadolinium contrast is administered, the longitudinal inversion recovery curve is sampled in three slices encompassing the left ventricle.